Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults.

Trial Profile

Multicenter, Double-Blind Randomized Study to Compare the Safety and Efficacy of Levofloxacin 750 mg Once Daily for Five Days vs. Levofloxacin 500 mg Once Daily for 10 Days in the Treatment of Mild to Severe Community-Acquired Pneumonia in Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2009

At a glance

  • Drugs Levofloxacin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2009 Actual patient number (530) added as reported by ClinicalTrials.gov.
    • 26 May 2009 Ortho-McNeil added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.
    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top